Systematic review and meta-analysis of the efficacy and safety of [¹⁷⁷Lu]Lu-edotreotide ([¹⁷⁷Lu]Lu-DOTATOC) for the treatment of neuroendocrine tumors.

ABSTRACT: [¹⁷⁷Lu]Lu-edotreotide is a radiopharmaceutical therapy (RPT) targeting somatostatin receptors, which are commonly overexpressed on neuroendocrine tumors (NETs). This systematic literature review and meta-analysis describes the efficacy and safety of [¹⁷⁷Lu]Lu-edotreotide in patients with NETs. To date, there has been no meta-analysis of data for this specific RPT. PubMed, EMBASE, Cochrane databases, and abstracts from select congresses were searched for eligible studies (February/October 2024). Meta-analysis was performed using fixed and random-effects models. The primary objective was to evaluate the efficacy of [¹⁷⁷Lu]Lu-edotreotide in terms of objective response rate (ORR; complete + partial response) in the subgroup of patients with gastro-enteropancrea

SUBMITTER: Baum RP 

PROVIDER: S-EPMC12799327 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature